These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 30009389)
1. NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis. Dorai T; Shah A; Summers F; Mathew R; Huang J; Hsieh TC; Wu JM Prostate; 2018 Nov; 78(15):1181-1195. PubMed ID: 30009389 [TBL] [Abstract][Full Text] [Related]
2. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305 [TBL] [Abstract][Full Text] [Related]
3. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528 [TBL] [Abstract][Full Text] [Related]
5. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants. Rashid MH; Babu D; Siraki AG Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969 [TBL] [Abstract][Full Text] [Related]
6. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Gong X; Kole L; Iskander K; Jaiswal AK Cancer Res; 2007 Jun; 67(11):5380-8. PubMed ID: 17545619 [TBL] [Abstract][Full Text] [Related]
7. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations. den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794 [TBL] [Abstract][Full Text] [Related]
8. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides. Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361 [TBL] [Abstract][Full Text] [Related]
9. NRH:quinone oxidoreductase 2 (NQO2) protein competes with the 20 S proteasome to stabilize transcription factor CCAAT enhancer-binding protein α (C/EBPα), leading to protection against γ radiation-induced myeloproliferative disease. Xu J; Patrick BA; Jaiswal AK J Biol Chem; 2013 Nov; 288(48):34799-808. PubMed ID: 24142791 [TBL] [Abstract][Full Text] [Related]
10. An Axis between the Long Non-Coding RNA Nakashima C; Fujiwara-Tani R; Mori S; Kishi S; Ohmori H; Fujii K; Mori T; Miyagawa Y; Yamamoto K; Kirita T; Luo Y; Kuniyasu H Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142607 [TBL] [Abstract][Full Text] [Related]
11. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627 [TBL] [Abstract][Full Text] [Related]
12. The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2). Riches Z; Liu Y; Berman JM; Walia G; Collier AC J Biochem Mol Toxicol; 2017 Aug; 31(8):. PubMed ID: 28346733 [TBL] [Abstract][Full Text] [Related]
13. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Gaikwad NW; Yang L; Rogan EG; Cavalieri EL Free Radic Biol Med; 2009 Jan; 46(2):253-62. PubMed ID: 18996184 [TBL] [Abstract][Full Text] [Related]
14. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Strassburg A; Strassburg CP; Manns MP; Tukey RH Mol Pharmacol; 2002 Feb; 61(2):320-5. PubMed ID: 11809856 [TBL] [Abstract][Full Text] [Related]
15. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mandal RK; Nissar K; Mittal RD Mol Biol Rep; 2012 Dec; 39(12):11145-52. PubMed ID: 23054000 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Dorai T; Dutcher JP; Dempster DW; Wiernik PH Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424 [TBL] [Abstract][Full Text] [Related]
17. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Jamieson D; Tung AT; Knox RJ; Boddy AV Br J Cancer; 2006 Nov; 95(9):1229-33. PubMed ID: 17031400 [TBL] [Abstract][Full Text] [Related]
18. Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Ahn KS; Gong X; Sethi G; Chaturvedi MM; Jaiswal AK; Aggarwal BB Cancer Res; 2007 Oct; 67(20):10004-11. PubMed ID: 17942934 [TBL] [Abstract][Full Text] [Related]
20. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems. Yan C; Dufour M; Siegel D; Reigan P; Gomez J; Shieh B; Moody CJ; Ross D Biochemistry; 2011 Aug; 50(31):6678-88. PubMed ID: 21718050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]